Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPER study of eltrombopag for sustained remission in relapsed or steroid-refractory immune thrombocytopenia
2018-000452-18Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by Novartis. Primary endpoint: Sustained remission by month 12. Started Jul 2018; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2018-000452-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000452-18.